$2.6 Million Accelerates Anti-Biofilm Vaccine to Prevent Bacterial Infections

Combating Antibiotic-Resistant Biopharmaceutical Accelerator (CARB-X) today announced it awarded Clarametyx Biosciences $2.6 million to develop an anti-biofilm vaccine. 

Clarametyx's CMTX-301 is a pathogen-agnostic vaccine candidate designed to prevent bacterial biofilm formation and allow the body's immune response to clear infections without antibiotics.

Biofilms enable bacteria to infect medical devices and human tissues, shielding them from natural clearance mechanisms. Bacterial biofilms are increasingly recognized to be involved in clinical infections in many body systems, including the auditory, cardiovascular, digestive, integumentary, reproductive, respiratory, and urinary systems.

"CARB-X is proud to continue supporting Clarametyx Biosciences in work to combat biofilm-associated infections, a major challenge in the fight against antibiotic resistance," said Erin Duffy, PhD, R&D Chief of CARB-X, in a press release on January 7, 2025. 

"With their novel anti-biofilm vaccine, CMTX-301, Clarametyx is taking an innovative approach that could transform how we prevent and treat these difficult-to-address infections. We look forward to seeing the impact of this program as it advances through clinical development."

CARB-X provided an initial overview of Clarametyx's work on novel anti-biofilm technologies.